Inclusion Criteria

- INCLUSION CRITERIA:

- Adult subjects (greater than or equal to18 years old), with documented malignancy,
with at least one solid tumor greater than or equal to 1 cm in diameter (not within
the liver), who are scheduled to enroll in an NCI therapy protocol using one of the
anti-angiogenic therapy agents (Vandetanib, Cediranib or Bevacizumab)

- The subject has a platelet count of 150,000 x 10(6)/L, hemoglobin value of greater
than 9 g/dL, PT and an aPTT less than 2 times normal limits.

- The subject has a clinically acceptable medical history, physical examination and
vital signs findings during the screening period (from less than 4 weeks before
administration of Fluciclatide (18F) Injection); i.e. Eastern Cooperative Oncology
Group (ECOG) performance score of 0 to 2.

- The subject has had no open surgical wounds in close proximity to the target
lesion(s) within 10 days prior to study entry.

- The subject has not had a biopsy of the target lesion within 7 days of PET/CT
imaging.

- The subject has not had radiation therapy to the region of the target lesion.

- Enrolling in the following NCI anti-angiogenic therapy protocols:

08-C-0020

09-C-0192

07-C-0058

09-C-0019

EXCLUSION CRITERIA:

- The subject is pregnant or lactating.

- The subject is being treated with doses of heparin or warfarin resulting in elevation
of PT or aPTT greater than 2 times normal.

- The subject has received any anti-angiogenic agent (e.g. bevacizumab, sorafenib,
sunitinib) within 60 days prior to pre-treatment (baseline) [18F]fluciclatide PET
imaging. This stipulation does not apply after the baseline [18F]fluciclatide PET
imaging.

- The subject has received another investigational medicinal product (IMP) within 24
hours before or is scheduled to receive another IMP within 24 hours after
Fluciclatide (18F) Injection.

- The subject has any contraindication to any of the study procedures, products used or
its constituents (e.g. severe claustrophobia unrelieved by oral anxiolytics).

- The subject is unable to lie still for 75 minutes.

- The subject is known to have a history of hyper- or hypo-coagulation syndromes
resulting in prolongation of bleeding parameters. Such coagulopathies include but are
not limited to Von Willebrand disease, Protein C deficiency, Protein S deficiency,
Hemophilia A/B/C, Factor-V Leiden, and Bernard-Soulier syndrome.

- The subject has undergone a surgical procedure to the target lesion within 28 days
prior to baseline [18F]fluciclatide administration OR is scheduled to undergo a
surgical procedure between the baseline and post 1-cycle [18F]fluciclatide PET/CT.

- The subject has only bone metastasis

ADDITIONAL INCLUSION CRITERIA FOR SUBJECTS UNDERGOING OPTIONAL MR:

-Serum creatinine within 2 weeks prior to MRI less than or equal to 1.8mg/dl and estimated
glomerular filtration rate (eGFR) must be greater than 30 ml/min/1.73m(2).

ADDITIONAL EXCLUSION CRITERIA FOR SUBJECTS UNDERGOING OPTIONAL MR:

- The subject has known allergy to gadolinium

- The subject has contraindications to MRI:

- Subjects must weigh less than 136 kg (weight limit for scanner table).

- Subjects cannot have pacemakers, cerebral aneurysm clips, shrapnel injury, or
other implanted electronic devices or metal not compatible with MRI.